↓ Skip to main content

Acute Leukemias II

Overview of attention for book
Cover of 'Acute Leukemias II'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Myelodysplastic syndromes: preleukemic or early leukemic conditions?
  3. Altmetric Badge
    Chapter 2 Mechanisms of autocrine and paracrine growth control in acute myelogenous leukemia.
  4. Altmetric Badge
    Chapter 3 Clonal Analysis of Human Leukemias by Molecular Genetic Approaches
  5. Altmetric Badge
    Chapter 4 Clinical Relevance of Cytogenetics in Acute Leukemia
  6. Altmetric Badge
    Chapter 5 Minimal residual disease in acute leukemia: lessons learned from animal models.
  7. Altmetric Badge
    Chapter 6 Toward Improvement of Therapeutic Strategies in Leukemia by Amplification of the Immune Responses Against Leukemia
  8. Altmetric Badge
    Chapter 7 Double marker analysis for terminal deoxynucleotidyl transferase and myeloid antigens in acute nonlymphocytic leukemia patients and healthy subjects.
  9. Altmetric Badge
    Chapter 8 Antigen Receptor Rearrangement and Expression in Acute Leukemias
  10. Altmetric Badge
    Chapter 9 Immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  11. Altmetric Badge
    Chapter 10 Heterogeneity in protein patterns of CGL blast crisis cells: discrimination between lymphatic and myeloic lineages.
  12. Altmetric Badge
    Chapter 11 Correlation between the expression of myelomonocytic surface antigens and ultrastructural demonstration of early myeloperoxidase expression in null-AL(L) cells.
  13. Altmetric Badge
    Chapter 12 Interleukin-1 Production in Childhood Acute Lymphoblastic Leukemia During Chemo- and Radiotherapy According to BFM (Berlin-Frankfurt-Münster) Protocol
  14. Altmetric Badge
    Chapter 13 Determination of Soluble Interleukin-2 Receptors After Bone Marrow Transplantation
  15. Altmetric Badge
    Chapter 14 Synergism of H2 Histamine Receptor Antagonists with Alpha-Interferon to Inhibit the Growth of Leukemic and Normal Hematopoietic Progenitors
  16. Altmetric Badge
    Chapter 15 Dependence of serum erythropoietin level on erythropoiesis in leukemia.
  17. Altmetric Badge
    Chapter 16 Transferrin derivatives with growth factor activities in acute myeloblastic leukemia: an autocrine/paracrine pathway.
  18. Altmetric Badge
    Chapter 17 In vitro effects of G-CSF, GM-CSF, and IL-3 on leukemic cells of children with acute nonlymphoblastic leukemia.
  19. Altmetric Badge
    Chapter 18 In Vitro Growth Kinetics of Myeloid Progenitor Cells of Myelodysplastic Patients in Response to Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3
  20. Altmetric Badge
    Chapter 19 Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia:Augmentation of LAK-Cell Cytotoxicity by Combinations of Lymphokines or Cytokines
  21. Altmetric Badge
    Chapter 20 Biochemical Evidence for Synergistic Combination Treatment with Methotrexate and 6-Mercaptopurine in Acute Lymphoblastic Leukemia
  22. Altmetric Badge
    Chapter 21 Pharmacokinetics of Folinic Acid in Children with Acute Lymphoblastic Leukemia
  23. Altmetric Badge
    Chapter 22 Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
  24. Altmetric Badge
    Chapter 23 Synergistic Cytotoxicity of Cytosine Arabinoside and Mitoxantrone for K562 and CFU-GM
  25. Altmetric Badge
    Chapter 24 Mafosfamide Induces Less Sister Chromatid Exchange in Ph-Positive Cells Than in Normal Bone Marrow
  26. Altmetric Badge
    Chapter 25 Blood Concentration of Ascorbyl-Free Radical in Children with Acute Lymphoblastic Leukemia:Preliminary Report
  27. Altmetric Badge
    Chapter 26 Association of GP40/CD7+ acute myeloblastic leukemia and chromosome 5 aberrations.
  28. Altmetric Badge
    Chapter 27 Acute monocytic leukemia with translocation t(1;11) (p31;q23): simultaneous staining of chromosomes and cell surface antigens.
  29. Altmetric Badge
    Chapter 28 Prognostic significance of chromosome analysis in de novo acute myeloid leukemia.
  30. Altmetric Badge
    Chapter 29 Chromosomal aberrations in childhood acute nonlymphoblastic leukemia.
  31. Altmetric Badge
    Chapter 30 Cytogenetic study of 130 childhood acute nonlymphocytic leukemias.
  32. Altmetric Badge
    Chapter 31 Changes in Clonal Growth, Immunophenotype, and Morphology During a Follow-up Study of an Acute Lymphoblastic Leukemia
  33. Altmetric Badge
    Chapter 32 Prognostic Significance of the Karyotype in Patients with Primary Myelodysplastic Syndrome
  34. Altmetric Badge
    Chapter 33 Update of the Cytogenetic Study of Childhood Non-High-Risk Acute Lymphocytic Leukemia at Diagnosis in Protocol VI of the Dutch Childhood Leukemia Study Group
  35. Altmetric Badge
    Chapter 34 Prognosis and DNA Aneuploidy in Children with Acute Lymphoblastic Leukemia
  36. Altmetric Badge
    Chapter 35 Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
  37. Altmetric Badge
    Chapter 36 Intensive sequential chemotherapy for children with acute myelogenous leukemia.
  38. Altmetric Badge
    Chapter 37 Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988).
  39. Altmetric Badge
    Chapter 38 Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
  40. Altmetric Badge
    Chapter 39 High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia.
  41. Altmetric Badge
    Chapter 40 Therapy of childhood acute myelogenous leukemia: an update of the AIEOP/LAM 8204 study. Italian Pediatric Hematology-Oncology Association.
  42. Altmetric Badge
    Chapter 41 Prognostic Significance of Eosinophilia in Acute Myelomonocytic Leukemia in Relation to Induction Treatment
  43. Altmetric Badge
    Chapter 42 Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84.
  44. Altmetric Badge
    Chapter 43 Morphology, immunology, cytochemistry, and cytogenetics and the classification of subtypes in AML.
  45. Altmetric Badge
    Chapter 44 Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
  46. Altmetric Badge
    Chapter 45 Therapy of acute myelogenous leukemia in adults.
  47. Altmetric Badge
    Chapter 46 Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
  48. Altmetric Badge
    Chapter 47 Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
  49. Altmetric Badge
    Chapter 48 Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.
  50. Altmetric Badge
    Chapter 49 EORTC Leukemia Group trials on acute myeloid leukemias: an overview.
  51. Altmetric Badge
    Chapter 50 A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
  52. Altmetric Badge
    Chapter 51 Predictive models for achievement of complete remission and duration of first remission in adult acute myeloid leukemia.
  53. Altmetric Badge
    Chapter 52 Sequential decision strategy of the AML Cooperative Group studies.
  54. Altmetric Badge
    Chapter 53 Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis.
  55. Altmetric Badge
    Chapter 54 Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia. - PubMed - NCBI
  56. Altmetric Badge
    Chapter 55 Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
  57. Altmetric Badge
    Chapter 56 Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
  58. Altmetric Badge
    Chapter 57 Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
  59. Altmetric Badge
    Chapter 58 Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.
  60. Altmetric Badge
    Chapter 59 Mitoxantrone in the treatment of acute leukemia.
  61. Altmetric Badge
    Chapter 60 Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
  62. Altmetric Badge
    Chapter 61 Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
  63. Altmetric Badge
    Chapter 62 Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
  64. Altmetric Badge
    Chapter 63 Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
  65. Altmetric Badge
    Chapter 64 Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
  66. Altmetric Badge
    Chapter 65 Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.
  67. Altmetric Badge
    Chapter 66 Acute promyelocytic leukemia: clinical findings and therapeutic results in 30 patients.
  68. Altmetric Badge
    Chapter 67 Magnetic Resonance Imaging Follow-up in Patients with Acute Leukemia During Induction Chemotherapy
  69. Altmetric Badge
    Chapter 68 Thrombin generation in acute myeloblastic leukemia.
  70. Altmetric Badge
    Chapter 69 Acute megakaryoblastic leukemia: a case report.
  71. Altmetric Badge
    Chapter 70 Acute megakaryoblastic leukemia (FAB-M7) in an infant presenting with orbital chloroma and meningeal involvement.
  72. Altmetric Badge
    Chapter 71 Risk of leukemic transformation in two types of acquired idiopathic sideroblastic anemia.
  73. Altmetric Badge
    Chapter 72 Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
  74. Altmetric Badge
    Chapter 73 Chronic Myelomonocytic Leukemia: Clinical Data, Morphological Features, and Outcome in 56 Patients
  75. Altmetric Badge
    Chapter 74 Chemotherapy of acute myeloid leukemia of 35- to 60-year-old patients.
  76. Altmetric Badge
    Chapter 75 Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia.
  77. Altmetric Badge
    Chapter 76 Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: a Preliminary Multicentric Study
  78. Altmetric Badge
    Chapter 77 Intensive Chemotherapy for Acute Lymphoblastic Leukaemia in Adults
  79. Altmetric Badge
    Chapter 78 Clinical Importance of T-ALL Subclassification According to Thymic or Prethymic Maturation Stage
  80. Altmetric Badge
    Chapter 79 Treatment of Adult Acute Lymphoblastic Leukaemia
  81. Altmetric Badge
    Chapter 80 Treatment of Relapsed Acute Lymphocytic Leukemia in Adults
  82. Altmetric Badge
    Chapter 81 Results and Significance of Six Randomized Trials in Four Consecutive ALL-BFM Studies
  83. Altmetric Badge
    Chapter 82 Cytogenetics of Childhood Acute Lymphoblastic Leukemia in Multicenter Trials
  84. Altmetric Badge
    Chapter 83 More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials.
  85. Altmetric Badge
    Chapter 84 Treatment of Acute Lymphoblastic Leukemia: Protocol Fralle 83–85
  86. Altmetric Badge
    Chapter 85 Dutch Childhood Leukemia Study Group: Early Results of Study ALL VI (1984–1988)
  87. Altmetric Badge
    Chapter 86 Results of Acute Lymphoblastic Leukemia Therapy in Childhood: GDR-Experiences 1981–1987
  88. Altmetric Badge
    Chapter 87 Impact of Early Intensive Reinduction Therapy on Event-Free Survival in Children with Low-Risk Acute Lymphoblastic Leukemia
  89. Altmetric Badge
    Chapter 88 Improved Prognosis for Childhood Acute Lymphocytic Leukemia with Very High White Blood Cell Count (> 100/nl) with Rotation of Non-Cross-Resistant Drug Combinations
  90. Altmetric Badge
    Chapter 89 Prognosis of Initial CNS Involvement in Acute Lymphoblastic Leukemia Childhood
  91. Altmetric Badge
    Chapter 90 Central Nervous System Relapse Prevention in 1165 Standard-Risk Children with Acute Lymphoblastic Leukemia in Five BFM Trials
  92. Altmetric Badge
    Chapter 91 Effective Prevention of Central Nervous System Leukemia with Intrathecal Methotrexate and Intrathecal Methotrexate, Cytosine Arabinoside, and Hydrocortisone in Childhood Acute Lymphocytic Leukemia
  93. Altmetric Badge
    Chapter 92 Risk of CNS Relapse After Systemic Relapse of Childhood Acute Lymphoblastic Leukemia
  94. Altmetric Badge
    Chapter 93 Incidence and Clinical Implications of Acute Hybrid Leukemia in Childhood
  95. Altmetric Badge
    Chapter 94 Prevention of Infection in Acute Leukemia
  96. Altmetric Badge
    Chapter 95 The Febrile Neutropenic Patient: Newer Options for Empirical Therapy
  97. Altmetric Badge
    Chapter 96 Supportive care of the marrow transplant recipient: the Seattle Experience.
  98. Altmetric Badge
    Chapter 97 Management of Fungal Infection in Neutropenic Patients with Fluconazole
  99. Altmetric Badge
    Chapter 98 Prevention of Bacteremias Caused by α-Hemolytic Streptococci by Roxithromycin in Patients Treated with Intensive Cytotoxic Treatment
  100. Altmetric Badge
    Chapter 99 Hepatosplenic Candidiasis in Acute Leukemias
  101. Altmetric Badge
    Chapter 100 Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
  102. Altmetric Badge
    Chapter 101 Preliminary Results of Treatment with Itraconazole in Patients with Systemic Fungal Infections
  103. Altmetric Badge
    Chapter 102 Lymphocyte Contamination in Leukocyte-Depleted Red Cell and Platelet Concentrates Obtained by Filtration
  104. Altmetric Badge
    Chapter 103 Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.
  105. Altmetric Badge
    Chapter 104 Prospective study on the influence of disease or treatment on pituitary function in 31 children with acute leukemia and non-Hodgkin's lymphoma.
  106. Altmetric Badge
    Chapter 105 Incidence of aseptic osteonecrosis following the therapy of childhood leukemia.
  107. Altmetric Badge
    Chapter 106 Osteoporosis in Children with Leukemia: A Potentially Debilitating Anomaly?
  108. Altmetric Badge
    Chapter 107 Principles of Supportive Psychological Care for Patients Undergoing Bone Marrow Transplantation
  109. Altmetric Badge
    Chapter 108 Fibronectin in Stomatitis Therapy of Leukemic Children
  110. Altmetric Badge
    Chapter 109 Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
  111. Altmetric Badge
    Chapter 110 Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM).
  112. Altmetric Badge
    Chapter 111 Pharmacologically directed design of leukemia therapy.
  113. Altmetric Badge
    Chapter 112 Treatment of Relapsed or Refractory Acute Leukemia: Comparison of Two Different Regimens
  114. Altmetric Badge
    Chapter 113 BFM Group Treatment Results in Relapsed Childhood Acute Lymphoblastic Leukemia
  115. Altmetric Badge
    Chapter 114 Marrow Grafting for Acute Leukemia: Results and Future Treatment Strategies
  116. Altmetric Badge
    Chapter 115 Bone marrow transplantation from histocompatible sibling donors for patients with acute lymphoblastic leukemia.
  117. Altmetric Badge
    Chapter 116 Allogeneic Bone Marrow Transplantation in Childhood Leukemia: Results and Strategies in the Federal Republic of Germany
  118. Altmetric Badge
    Chapter 117 Allogeneic and Autologous Bone Marrow Transplantation in Acute Leukemia: The Essen Experience
  119. Altmetric Badge
    Chapter 118 Role of Cytokines and Major Histocompatibility Complex Antigens in Graft-Versus-Host Disease: In Vitro Studies Using T-Cell Lines and Keratinocytes or Hemopoietic Targets
  120. Altmetric Badge
    Chapter 119 Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in First Remission: First Dutch Prospective Study
  121. Altmetric Badge
    Chapter 120 Autologous Bone Marrow Transplantation for Acute Leukemia in Remission: An Analysis of 1322 Cases
  122. Altmetric Badge
    Chapter 121 Role of Autologous Bone Marrow Transplantation in Acute Leukemia
  123. Altmetric Badge
    Chapter 122 Long-term disease-free survival following autologous bone marrow/blood stem cell transplantation in 89 patients with acute leukemia.
  124. Altmetric Badge
    Chapter 123 Allogeneic and Autologous Bone Marrow Transplantation for Acute Lymphoblastic Leukemia
  125. Altmetric Badge
    Chapter 124 Treatment Strategies for Acute Lymphoblastic Leukemia
  126. Altmetric Badge
    Chapter 125 Influence of Treatment Modality, Patient/Donor Characteristics, and Disease Stage on the Risk of Relapse After Allogeneic Marrow Transplantation for Acute Leukemia
  127. Altmetric Badge
    Chapter 126 Comparison of Allogeneic and Autologous Bone Marrow Transplantation for Treatment of Acute Lymphocytic Leukemia in Childhood
  128. Altmetric Badge
    Chapter 127 High-dose chemotherapy with noncryopreserved autologous bone marrow transplantation for acute myeloid leukemia in first complete remission.
  129. Altmetric Badge
    Chapter 128 Myelopoietic reconstitution following autologous bone marrow transplantation.
  130. Altmetric Badge
    Chapter 129 Bone Marrow Transplantation with a Fixed Low Number of T-Cells in the Graft
  131. Altmetric Badge
    Chapter 130 Complotyping and Subtyping of MHC Class I Gene Products in Haplotype Determination for Bone Marrow Transplantation
  132. Altmetric Badge
    Chapter 131 Complications of Bone Marrow Transplantation in Chinese
  133. Altmetric Badge
    Chapter 132 Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Related Morbidity Induced by Myelotoxic Chemotherapy
  134. Altmetric Badge
    Chapter 133 Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor After Chemotherapy for Acute Leukemias at Higher Age or After Relapse
  135. Altmetric Badge
    Chapter 134 Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
  136. Altmetric Badge
    Chapter 135 Use of Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor To Speed Engraftment and Treat Graft Failure Following Marrow Transplantation in Man
  137. Altmetric Badge
    Chapter 136 Regeneration of Granulopoiesis with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor After Bone Marrow Transplantation
  138. Altmetric Badge
    Chapter 137 Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
  139. Altmetric Badge
    Chapter 138 Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

policy
1 policy source
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acute Leukemias II
Published by
Springer Berlin Heidelberg, December 2012
DOI 10.1007/978-3-642-74643-7
ISBNs
978-3-54-050984-4, 978-3-64-274643-7
Editors

Büchner, T., Schellong, G., Hiddemann, W., Ritter, J.